Highlights Sana Biotechnology, Inc.

Equities

SANA

US7995661045

Market Closed - Nasdaq Other stock markets 21:00:00 14/05/2024 BST			5-day change	1st Jan Change
8.6 ^USD	+8.72%		-14.34%	+110.78%

05-08	Sana Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-18	Sana Biotechnology, Inc. Announces Resignation of Douglas Williams as Executive Vice President and President, Research and Development	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sana Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	03-01	MT
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline	02-29	MT
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP	02-13	CI
Sana Biotechnology Says US FDA Approved Investigational New Drug Application to Launch Clinical Trial for SC262	01-05	MT
Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262	01-05	CI
Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting	12-11	CI
Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System	12-01	CI
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis	11-09	CI
Sana Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Sana Biotechnology, Inc. Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with A 2024 Operating Burn Under $200M	10/10/23	CI
Sana Biotechnology, Inc. Enters into Lease Termination Agreement with Pacific Commons Owner, LP	21/08/23	CI
Sana Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/08/23	CI
Sana Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/05/23	CI
Sana Biotechnology, Inc. Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model	12/04/23	CI
SANA BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	16/03/23	AQ
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	16/03/23	CI
Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	16/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sana Biotechnology, Inc.

Equities

SANA

US7995661045

Highlights

Filters